Non-Clinical Efficacy and Safety Studies on G1XCGD, a lentiviral vector for ex vivo gene therapy of Chronic Granulomatous Disease

1Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Frankfurt, Germany 2Division of Hematology/Oncology, Boston Children’s Hospital, Boston, Massachusetts, USA. 3Harvard Medical School, Boston, Massachusetts, USA 4Hannover Medical School, Institute of Experimental Hematology, Hannover, Germany 5Centre for Immunodeficiency, UCL Institute of Child Health, and Great Ormond Street Hospital for Children NHS Trust London, UK 6Genethon, Evry, France 7LOEWE-Research Group, Paul-Ehrlich-Institute, Langen, Germany 8Hannover Medical School, Cluster of Excellence REBIRTH, Hannover, Germany